following a full submission:
ustekinumab (Stelara®) is accepted for use within NHSScotland.
Indication under review: For the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic or have medical contraindications to such therapies.
In a phase III study in patients with moderate to severe ulcerative colitis who had failed prior therapy, clinical remission was achieved by a significantly greater proportion of patients who received ustekinumab compared with placebo.
This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.
Medicine details
- Medicine name:
- ustekinumab (Stelara)
- SMC ID:
- SMC2250
- Indication:
For the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic or have medical contraindications to such therapies.
- Pharmaceutical company
- Janssen-Cilag Ltd
- BNF chapter
- Gastro-intestinal system
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 13 April 2020